Zacks Investment Research on MSN10h
Vertex Pharmaceuticals (VRTX) Advances While Market Declines: Some Information for Investors
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $502.55, marking a +0.45% move from the previous day. The stock's change was more than the S&P 500's daily loss of 0.33%. At the ...
Investing Snacks1d
Vertex Climbs Higher: Investors Catch the Pharma Fever
Proficio Capital Partners cranked up its position in Vertex Pharmaceuticals by 46.6% during the fourth quarter, grabbing 978 ...
Zacks Investment Research on MSN1d
Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock
Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...
Analysts Are Bullish on Top Healthcare Stocks: Vera Therapeutics (VERA), Erasca (ERAS)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vera Therapeutics (VERA – Research Report), ...
Investing Snacks2d
Painfully Profitable: Vertex’s Shot Beyond CF
Vertex Pharmaceuticals is flexing its innovation muscles beyond its cystic fibrosis stronghold, charging into new territories ...
Managed Healthcare Executive2d
Non-Opioid Pain Drug Journavx Gaining Traction
According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...
Analysts Have Conflicting Sentiments on These Healthcare Companies: Nevro Corp (NVRO), Globus Medical (GMED) and Vertex Pharmaceuticals (VRTX)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Nevro Corp (NVRO – Research Report), Globus ...
Vertex Pharmaceuticals Inc. stock rises Monday, still underperforms market
Shares of Vertex Pharmaceuticals Inc. VRTX rallied 1.70% to $511.74 Monday, on what proved to be an all-around great trading ...
BioPharma Dive3d
Verve gets FDA green light to expand base editing trial into US
The company expects next quarter to read out initial data from its Heart-2 trial, which is testing a one-time treatment for ...
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors
This was the stock's second consecutive day of losses.
Gene therapy loses luster as investors eye quicker returns from weight-loss drugs
In the last year, some drugmakers have pulled back from the sector, including Pfizer, which recently stopped selling its gene ...